Abstract:e21041 Background: Gefitinib is first-line therapy for patients with EGFR-activating mutation in non-small cell lung cancer (NSCLC). Meanwhile, ̃30% patients were progression within 12 months even harboring EGFR-activating mutation. Furthermore, integrative scoring models for prediction of gefitinib outcomes are still lacking. Variations in genes of DNA repair and cell cycle pathway may have potential impacts on proliferation, migration and invasion of tumor cells. Therefore, we investigated a series of single nucleotide polymorphisms (SNP) in DNA repair and cell cycle genes based on an efficient algorithm machine learning algorithm for establishing an integrative scoring system for survival prediction following gefitinib therapy in NSCLC patients. Methods: A total of 282 patients with activating EGFR mutations were enrolled and divided into train cohort and test cohort, randomly. 125 SNPs in 47 candidate genes were selected by Heploview 4.2 and sequenced by Agena MassARRAY System. Predictive features were selected by randomForestSRC, an efficient algorithm machine learning algorithm to analyze survival data, for PFS following gefitinib therapy. The top candidate variables were presented into COX regression models with hazard ratio as weight for each predictor (HR = 1-1.49 = 1; HR = 1.5-2.49 = 2; HR = 2.5-3.49 = 3), providing p < 0.1. This study was approved by the ethical committee of Sun Yat-Sen University Cancer Center. Results: The progression risk predictive model was established by random forest survival and validated by COX regression analysis, included XRCC1 rs3213263(CT vs CC, RR = 1.997, 95%CI = 1.314-3.036, p = 0.001), FOXO3 rs75544369(GA vs GG, RR = 1.942, 95%CI = 1.139-3.309, p = 0.012), FOXM1 rs2302257(CC vs GG, RR = 2.889, 95%CI = 1.477-5.691, p = 0.002) and ERCC1 rs10408989(TT vs GT, RR = 1.735, 95%CI = 1.152-2.613, p = 0.008; GG vs GT, RR = 3.788, 95%CI = 1.625-8.832, p = 0.002). The progression risk score ranged from 0-10. 49 patients (25.52%) and 20 patients (22.22%) were scored 0, 18(9.38%) and 10(11.11%) patients were scored more than 5 in train cohort and test cohort, respectively. According to the risk score of patients, we divided the patients into four groups, the median PFS were 26.23(95%CI:14.23-35.37), 16.80(95%CI:12.87-23.60), 11.13(95%CI:8.87-16.70) and 6.25 (95% CI:4.43-11.67) months for 0, 2, 3&4 and ≥5 group (p < 0.0001) in the train cohort. Meanwhile, the median PFS were 18.80(95%CI:11.80-64.53),13.60(95%CI:9.17-27.33), 13.47(95%CI:9.83-18.40), 13.47(95%CI:9.83-18.40) and 7.40(95%CI:3.33- NA) months for 0, 2, 3&4 and ≥5 group in validation cohort (p = 0.0017). Conclusions: The risk score system is a simple tool for risk stratification in patients undergoing gefitinib. Widespread application of the score system will require further independent validation.

Development and Validation of a Concise Prediction Scoring System for Asian Lung Cancer Patients with <i>EGFR</i> Mutation Before Treatment

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Development and validation of a multivariable predictive model for EGFR gene mutation status in patients with lung adenocarcinoma

Establishment and Evaluation of EGFR Mutation Prediction Model Based on Tumor Markers and CT Features in NSCLC

Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data.

Nomogram prediction for epidermal growth factor receptor mutation and subtypes in patients with non-small cell lung cancer

Accurate prediction of epidermal growth factor receptor mutation status in early-stage lung adenocarcinoma, using radiomics and clinical features

An Integrative Scoring System for Survival Prediction Following Gefitinib Therapy in Non-Small Cell Lung Cancer: from a Long-Term Real-World Study.

Establishment of prognostic nomograms for predicting the progression free survival of EGFR ‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs

The Potential Of Radiomics Nomogram In Non-Invasively Prediction Of Epidermal Growth Factor Receptor Mutation Status And Subtypes In Lung Adenocarcinoma

Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer

A predictive model of computed tomography and clinical features of EGFR gene mutation in lung adenocarcinoma

Clinical and Radiological Predictors of Epidermal Growth Factor Receptor Mutation in Nonsmall Cell Lung Cancer.

The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA

Predicting EGFR Mutation Status in Lung Adenocarcinoma: Development and Validation of a Computed Tomography-Based Radiomics Signature.

Dual-energy CT-based Radiomics in Predicting EGFR Mutation Status Non-Invasively in Lung Adenocarcinoma

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Development and Validation of Machine Learning Models to Predict Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Multi-Center Retrospective Radiomics Study

Correlations Study Between 18 F-FDG PET/CT Metabolic Parameters Predicting Epidermal Growth Factor Receptor Mutation Status and Prognosis in Lung Adenocarcinoma.

Development and Validation of a Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV EGFR-mutant Non-Small Cell Lung Cancer.

Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients